Systemic AvailabilitySistineNCT06082726
The Systemic Concentration of Short-Chain Fatty Acids After Delivery in the Small and Large Intestine of Healthy Volunteers
A study testing SCFA in people with Systemic Availability and Intestinal Absorption, run by KU Leuven at 1 site in Belgium.
Trial summary
The goal of this crossover study is to evaluate the systemic availability of short-chain fatty acids (SCFA) that are either administered in the small intestine or the colon in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Systemic Availability, Intestinal Absorption, Metabolism
- What is being tested?
- SCFA
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteBelgium
- Study dates
- 9 Oct 2023to 11 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- female and male
- healthy participants
- age within 18 - 50 years
- normal BMI (18.5-25 kg/m^2)
Who cannot join
- Chronic gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, chronic constipation (less than 3 stools a week) and chronic frequent diarrhoea (more than 3 stools a day)
- Previous abdominal surgery, except from appendectomy
- Being on a weight loss, gluten-free, lactose-free, or vegan diet
- The donation of blood during the last 3 months or suffering from low blood haemoglobin levels
- The use of antibiotics or other medication that affects the gastrointestinal tract 3 months preceding the study and/or during the study
- The use of prebiotics or probiotics 2 weeks preceding the study and/or during the study
- Pregnancy, lactation or wish to become pregnant during the study period
- Previous or current substance/alcohol dependence or abuse (> 2 units per day/14 units per week)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Systemic Availability of Short-Chain Fatty Acids After Delivery in the Small Intestine and the Colon
The goal of this crossover study is to evaluate the systemic availability of short-chain fatty acids (SCFA) that are either administered in the small intestine or the colon in healthy volunteers. The main question it aims to answer is whether the site of administration affects the amount of SCFA that reaches the systemic circulation. On two test days participants will ingest capsules filled with SCFA that are specifically delivered in the small intestine or the colon. After ingestion, blood samples will be collected at regular time points.
- Being tested
- SCFA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SCFADietary supplement
Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
| Study group | Role | What they receive |
|---|---|---|
| small intestinal delivery capsules | Experimental | Participants will ingest small intestinal delivery capsules filled with short-chain fatty acids. Receives: Dietary Supplement: SCFA |
| Colon-delivery capsules | Experimental | Participants will ingest colon-delivery capsules filled with short-chain fatty acids. Receives: Dietary Supplement: SCFA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of 13C-short-chain fatty acids in blood
Assessed by analysing SCFA in blood samples collected at regular time points
Measured: up to 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2023
- Study start9 Oct 2023
- Primary completion11 Mar 2024
- Study completion11 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic AvailabilityStudies of the same condition, open and under way.
- More trials run by KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kristin Verbeke, KU Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06082726
- Sponsor's protocol ID
- S67256
- Acronym
- Sistine
- Status last verified
- Oct 2023
- First submitted
- 9 Oct 2023
- Last updated
- 23 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No IPD data will be shared with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Systemic Availability of Short-Chain Fatty Acids After Delivery in the Small Intestine and the Colon
- ClinicalTrials.gov ID
- NCT06082726
- Acronym / sponsor ID
- Sistine / S67256
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- KU LeuvenUniversity, hospital or other
- Study start
- 9 Oct 2023 (actual)
- Primary completion
- 11 Mar 2024 (actual)
- Study completion
- 11 Mar 2024 (actual)
- First posted
- 13 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this crossover study is to evaluate the systemic availability of short-chain fatty acids (SCFA) that are either administered in the small intestine or the colon in healthy volunteers. The main question it aims to answer is whether the site of administration affects the amount of SCFA that reaches the systemic circulation. On two test days participants will ingest capsules filled with SCFA that are specifically delivered in the small intestine or the colon. After ingestion, blood samples will be collected at regular time points.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| small intestinal delivery capsules | Experimental | Dietary Supplement: SCFAParticipants will ingest small intestinal delivery capsules filled with short-chain fatty acids. |
| Colon-delivery capsules | Experimental | Dietary Supplement: SCFAParticipants will ingest colon-delivery capsules filled with short-chain fatty acids. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- female and male
- healthy participants
- age within 18 - 50 years
- normal BMI (18.5-25 kg/m^2)
Key exclusion criteria (8 listed)
- Chronic gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, chronic constipation (less than 3 stools a week) and chronic frequent diarrhoea (more than 3 stools a day)
- Previous abdominal surgery, except from appendectomy
- Being on a weight loss, gluten-free, lactose-free, or vegan diet
- The donation of blood during the last 3 months or suffering from low blood haemoglobin levels
- The use of antibiotics or other medication that affects the gastrointestinal tract 3 months preceding the study and/or during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SCFAParticipants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours. | Dietary supplement | Colon-delivery capsules, small intestinal delivery capsules |
Primary outcome
Concentration of 13C-short-chain fatty acids in blood
Time frame: up to 12 hours
Assessed by analysing SCFA in blood samples collected at regular time points
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
- Individual participant dataSharing planned: No. No IPD data will be shared with other researchers.
Related trials for Systemic Availability
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
RecruitingPhase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Chronic Graft-versus-host-disease
Active, not recruitingPhase 3
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Chronic Graft-versus-host-disease
RecruitingObservational study
FDG PET-CT in Advanced Breast Cancer
Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available, If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SCFA in people with Systemic Availability and Intestinal Absorption, run by KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of 13C-short-chain fatty acids in blood (time frame: up to 12 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.